Creative Biolabs delivers strategic molecular roadmaps designed to overcome tumor immune evasion. Our core solution is the targeted reversal of immune evasion mechanisms by pinpointing the exact failure point in the antigen processing and presentation (APP) pathway. Clients gain essential, non-obvious deliverables, including high-resolution mapping of major histocompatibility class (MHC) I/II downregulation, transporter-associated with antigen processing (TAP) transporter dysfunction, and oncoprotein-mediated pathway interference. This detailed analysis maximizes your therapeutic strategy by identifying and validating novel targets that restore effective anti-tumor immunity.

The Immunological Bottleneck: Why ICIs Fail

The success of PD-1/PD-L1 blockade hinges on cytotoxic T lymphocytes (CTLs) recognizing tumor antigens via MHC I molecules. The seminal mechanism of adaptive immune evasion is the tumor's disruption of this vital pathway. Tumor cells deploy sophisticated tactics, including the loss of antigenicity and, most crucially, MHC I downregulation, effectively rendering them "invisible" to CD8+ T cells. Furthermore, tumors often exhibit dysfunctional antigen processing machinery (APM), with altered expression of components like the TAP transporter or immunoproteasome subunits. The therapeutic benefit of immune checkpoint inhibitors (ICIs) is therefore proportional to the efficiency of the tumor's APP pathway.

Strategic Research Solutions

Do you know the precise molecular scar driving resistance in your cohort? Speak with a Creative Biolabs specialist to map your mechanism today.

Workflow: Comprehensive & Transparent Molecular Roadmap

Our service is structured to provide a comprehensive and detailed explanation of the molecular mechanisms driving immune evasion, suitable for visualization as a clear, professional flowchart.

Publication

This review examines how defects in the antigen processing and presentation machinery enable tumors to evade immune detection. It highlights that such defects are a major mechanism of primary and acquired resistance to ICI therapy, limiting its efficacy. The authors argue that modulating intracellular antigen processing—particularly targeting enzymes like ERAP1/ERAP2—represents a promising combinatorial strategy to enhance tumor immunogenicity and improve patient responses to cancer immunotherapy.

Fig.1 Molecular defects in the antigen presentation machinery underlie immune evasion by tumors. ¹

Why Choose Us?

Creative Biolabs stands apart by focusing rigorously on the causality of immune evasion, definitively measuring the actual MHC I peptide load—the single most important metric for T cell recognition—which RNA-only services cannot provide. Our key advantage is the unparalleled multi-omic integration of high-resolution mass spectrometry (to quantify peptide output) with single-cell RNA-seq (to identify expression faults). This integration allows us to tackle complex challenges like viral oncogene-driven cancers. Our proprietary APM signature score provides APP-based biomarker superiority, predicting response to checkpoint blockade with superior resolution compared to conventional tumor mutational burden (TMB) or PD-L1. This delivers deep mechanistic intellectual property (IP) by defining precise, factor-driven mechanisms of immune evasion, enabling novel target identification.

Experience the Creative Biolabs Advantage - Get a Quote Today

FAQs

Customer Review

• Deep Mechanistic IP
  Using service in our research has significantly facilitated the identification of specific, actionable small molecule targets that directly reverse APP failure. We now target the mechanism of evasion, not just the checkpoint. – J**n* R****r
• Translational Validation
  Using Creative Biolabs' service in our research has improved linking our molecular expression data to a functional biological outcome via the in vitro T cell activation assays, which was essential for progressing our drug candidate. – Pl H*n

Related Services

To fully leverage the mechanistic data provided by the antigen processing and immune checkpoint-exposure impact analysis service, Creative Biolabs offers several complementary services:

How to Contact Creative Biolabs

The future of oncology success is built on understanding the complex mechanisms of tumor immune evasion. Our service for carcinogenic factor analysis provides the necessary high-resolution, multi-omic data to move beyond observational biomarkers and implement truly rational, personalized combination strategies. Partner with Creative Biolabs to define the molecular scars, fix the immunological bottleneck, and unlock the full cytotoxic potential of your therapeutic candidates.

Reference

1. Mpakali, A., and E. Stratikos. "The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy." Cancers (Basel) 13.1 (2021). Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cancers13010134

For Research Use Only | Not For Clinical Use